[
    [
        {
            "time": "2018-03-01",
            "original_text": "Analysts’ Recommendations for Eli Lilly in March 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "analysts",
                    "recommendations"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for Eli Lilly in March 2018",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-03-05",
            "original_text": "Update on Eli Lilly’s Oncology Drugs Erbitux, Gemzar, Lartruvo",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "oncology drugs",
                    "Erbitux",
                    "Gemzar",
                    "Lartruvo"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Update on Eli Lilly’s Oncology Drugs Erbitux, Gemzar, Lartruvo",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-03-07",
            "original_text": "Performance of Eli Lilly’s Oncology Drugs Alimta, Cyramza in 2017",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "performance",
                    "Alimta",
                    "Cyramza"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Performance of Eli Lilly’s Oncology Drugs Alimta, Cyramza in 2017",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 2,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-03-10",
            "original_text": "Update on Eli Lilly’s Neuroscience Portfolio",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "neuroscience",
                    "portfolio"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "neuroscience"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Update on Eli Lilly’s Neuroscience Portfolio",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-03-12",
            "original_text": "Eli Lilly’s Immunology Business Saw Solid Growth in 2017",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "immunology",
                    "solid growth"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "immunology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s Immunology Business Saw Solid Growth in 2017",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 2,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)",
            "features": {
                "keywords": [
                    "Cramer",
                    "Mad Money",
                    "recap"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general market"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        }
    ]
]